Drug Chatter -- Tracking biopharma stock chatter

Profile for ArQule, Inc. (ARQL)

« Back to company index

ARQL Chatter Timeline

Stock Ticker for ARQL

Most Active Tweeters for ARQL

UserTweets
@storminvestor 2
@SPNewsAnalysis 2
@ohmsonite 1
@NewsToDesk 1
@intercooleronli 1

Recent Tweets for ARQL

storminvestor @storminvestor
ArQule, Inc. $ARQL Expected to Announce Earnings of -$0.11 Per Share https://t.co/AgjZDk8X5l
July 25th 2017, 3:07pm
SPNewsAnalysis @SPNewsAnalysis
ArQule, Inc. $ARQL Expected to Announce Earnings of -$0.11 Per Share https://t.co/WdEZDkAsdx
July 25th 2017, 3:07pm
StockSpotter @StockSpotter
$ARQL up 1.6% to 1.25 bullish at a cycle bottom #stocks #markets #trading https://t.co/XODN2Bzt6G
July 25th 2017, 11:07am
dailymailtimes @dailymailtimes
ArQule, Inc. $ARQL Set to Announce Earnings on Tuesday https://t.co/GQEAQoc3m4
July 25th 2017, 8:07am
SPNewsAnalysis @SPNewsAnalysis
ArQule, Inc. $ARQL Set to Announce Earnings on Tuesday https://t.co/rPpplDs3qd
July 25th 2017, 7:07am
storminvestor @storminvestor
ArQule, Inc. $ARQL Set to Announce Earnings on Tuesday https://t.co/BdGg3zLXIT
July 25th 2017, 7:07am
intercooleronli @intercooleronli
ArQule, Inc. $ARQL Set to Announce Earnings on Tuesday https://t.co/BmVxirckks
July 25th 2017, 7:07am
ohmsonite @ohmsonite
@clarklsn2001 I'm looking at $ARQL and $LPTX. Don't blame me if they tank since biotech is high risk high return ?. Good luck!
July 22nd 2017, 8:07pm
StockNewsNow @StockNewsNow
$ARQL ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017 https://t.co/f8OisIjzaN
July 21st 2017, 8:07am
efinancialpub @efinancialpub
RT @NewsToDesk: $ARQL: ArQule To Report Second Quarter 2017 Financial Results On …: https://t.co/KVoa5kN9Bi
July 21st 2017, 7:07am
stockboardinc @stockboardinc
$ARQL ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017... - https://t.co/0iqMu4zL3s
July 21st 2017, 7:07am
NewsToDesk @NewsToDesk
$ARQL: ArQule To Report Second Quarter 2017 Financial Results On …: https://t.co/KVoa5kN9Bi
July 21st 2017, 7:07am
Allstocknews @Allstocknews
$ARQL ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017 From our Stock News Alerts App
July 21st 2017, 7:07am
TheMarketsDaily @TheMarketsDaily
ArQule $ARQL Earning Positive News Coverage, Report Shows https://t.co/mci5hdi8Ur
July 13th 2017, 11:07am
ZolmaxNews @ZolmaxNews
ArQule $ARQL Earning Positive News Coverage, Report Shows https://t.co/w9gZP4gwqi
July 13th 2017, 8:07am
1stOncology @1stOncology
#ArQule Reports First Patient Dosed in Phase 1 Trial of BTK Inhibitor, #ARQ531, for B-cell Malignancies $ARQL https://t.co/YwT9KsHVJi
July 12th 2017, 10:07am
MaisaCorp @MaisaCorp
$ARQL Begins Dosing Patients in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies
July 11th 2017, 4:07pm
JNapodano @JNapodano
$ARQL - Started P1 with BTK ARQ531 for B-cell malignancies. Initiation is on-time with previous guidance. Helps “Credibility” score.
July 11th 2017, 2:07pm
kuritzmike @kuritzmike
RT @odibro: $ARQL Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies https://t.co/7JPq94YdAM
July 11th 2017, 2:07pm
pharma_sector @pharma_sector
#ArQule Announces First Patient Dosed In Phase I Trial Of BTK Inhibitor, ARQ 531, For B-Cel... Read more: https://t.co/bpauzYSVzA $ARQL
July 11th 2017, 12:07pm
fortint @fortint
RT @iciresearch: ArQule Announces First Patient Dosed in Ph 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies $ARQL https://t.co/9…
July 11th 2017, 12:07pm
Jake132013 @Jake132013
$ARQL Arqule Inc 1.33 Had 127,376 1 Month Highs. ARQL Last price 1.33 Last change +0.04 +3.10%. https://t.co/IWTwJshFms
July 11th 2017, 11:07am
FinSentS_NASDAQ @FinSentS_NASDAQ
$ARQL:US ArQule: First Patient Dosed In ARQ 531 Phase 1 Trial For B-cell Malignancies #ARQULE INC https://t.co/agO9V1HmAV #NASDAQ
July 11th 2017, 10:07am
StockNewsNow @StockNewsNow
$ARQL ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies https://t.co/Ioxs8suVQy
July 11th 2017, 9:07am
pharma_sector @pharma_sector
#ArQule: First Patient Dosed In ARQ 531 Phase 1 Trial For B-cell Malignancies. Read more: https://t.co/fb3SRpkAIN $ARQL
July 11th 2017, 9:07am
focusblood @focusblood
#lymsm Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies $arql
July 11th 2017, 9:07am
iciresearch @iciresearch
ArQule Announces First Patient Dosed in Ph 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies $ARQL https://t.co/9C9sNsrTtX
July 11th 2017, 8:07am
stockboardinc @stockboardinc
$ARQL ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignan... - https://t.co/0hqra74Gbv
July 11th 2017, 7:07am
odibro @odibro
$ARQL Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies https://t.co/7JPq94YdAM
July 11th 2017, 7:07am
Allstocknews @Allstocknews
$ARQL ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancie From our Stock News Alerts App
July 11th 2017, 7:07am
newswithvalue @newswithvalue
$ARQL: ArQule Announces First Patient Dosed in Phase 1 Trial of BTK …: https://t.co/d4BK6uABnw
July 11th 2017, 7:07am
IcemanTrading @IcemanTrading
$ARQL Testing a big trend breakout. Closed over the 200SMA today with increased volume. #ICEMAN https://t.co/1LSAH6TQJf
July 6th 2017, 8:07pm
pharma_sector @pharma_sector
#ArQule : Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress... Read more: https://t.co/CdwNEDa2Mh $ARQL
July 6th 2017, 8:07pm
Greatstockpix @Greatstockpix
$ARQL daily chart looks pretty good if today's move holds.
July 5th 2017, 2:07pm
pharma_sector @pharma_sector
#ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at EHA. Read more: https://t.co/Wg3M6kxaLG $ARQL
July 2nd 2017, 1:07am
MyAlliesTrading @MyAlliesTrading
$ARQL ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European... https://t.co/0aqG7ulK2m
July 1st 2017, 6:07am
sarwood @sarwood
$ARQL really good looking chart. D Cup and handle with the handle turning into its on C&H lol, first pt is 2.00
June 30th 2017, 11:06am
dailypoliticaln @dailypoliticaln
ArQule $ARQL Getting Favorable Media Coverage, Study Shows https://t.co/jnudCrN3X0
June 29th 2017, 12:06pm
InsiderAlertsIA @InsiderAlertsIA
$ARQL: New Insider Filing on Director MICHAEL D LOBERG: https://t.co/DGsj4dKLft
June 27th 2017, 12:06pm
confcalltran @confcalltran
ArQule director just picked up 1,000 shares https://t.co/qu0fZ7SRhq $ARQL
June 27th 2017, 10:06am
pennyomegaCRWE @pennyomegaCRWE
Law Firm Investigating $ARQL https://t.co/t0HQ4FZsG7
June 26th 2017, 5:06pm
biopadawan @biopadawan
RT @mngerfreedm: $ARQL Strategy and catalysts https://t.co/IrhnQJXpgn
June 26th 2017, 4:06pm
pharma_sector @pharma_sector
#ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress o... Read more: https://t.co/4FNJeAHxp0 $ARQL
June 26th 2017, 4:06pm
dailypoliticaln @dailypoliticaln
ArQule $ARQL Getting Somewhat Positive Press Coverage, Study Finds https://t.co/wOWF4h4xKT
June 26th 2017, 8:06am
biostockinfo @biostockinfo
RT @TomSilver39: $ARQL #EHA17 ARQ 531, A Reversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity In ABC-DLBCL And GCB-DLBCL https…
June 26th 2017, 12:06am
TomSilver39 @TomSilver39
$ARQL #EHA17 ARQ 531, A Reversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity In ABC-DLBCL And GCB-DLBCL https://t.co/9Tv0tzOqp4
June 25th 2017, 5:06pm
mngerfreedm @mngerfreedm
$ARQL Strategy and catalysts https://t.co/IrhnQJXpgn
June 25th 2017, 8:06am
StockTipRobot @StockTipRobot
A Whitehouse intern overheard that this stock is gonna be uuuge! So consider selling ArQule $ARQL #ProTip
June 24th 2017, 8:06am
StockNewsNow @StockNewsNow
$ARQL ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European... https://t.co/O2rni9z5OQ
June 23rd 2017, 2:06pm
kuritzmike @kuritzmike
RT @odibro: $ARQL Presents Preclinical Data for BTK Inhibitor, ARQ 531, at #EHA17 https://t.co/iP0apINKDS
June 23rd 2017, 7:06am

Contact © thinkBiotech LLC 2004 - 2017. All rights reserved.